Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells-Reference-Cited by-同舟云学术

Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells

Published:2016-11-14 Issue:12 Volume:126 Page:4640-4653
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Sherbenou Daniel W.,Aftab Blake T.,Su Yang,Behrens Christopher R.,Wiita Arun,Logan Aaron C.,Acosta-Alvear Diego,Hann Byron C.,Walter Peter,Shuman Marc A.,Wu Xiaobo,Atkinson John P.,Wolf Jeffrey L.,Martin Thomas G.,Liu Bin

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference59 articles.

1. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review;Fonseca;Leukemia,2009

2. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

3. SAR650984, a CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies — data from a dose-escalation phase I study;Martin;Blood,2013

4. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma-data from a dose-escalation phase I/II study;Plesner;Blood,2012

5. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

2. Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab;International Journal of Molecular Sciences;2024-08-01

3. Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions;Pharmaceuticals;2024-06-25

4. The complement regulatory protein CD46 serves as a novel biomarker for cervical cancer diagnosis and prognosis evaluation;Frontiers in Immunology;2024-06-11

5. Complement regulatory protein CD46 promotes bladder cancer metastasis through activation of MMP9;International Journal of Oncology;2024-05-31